Live biotherapeutic products (LBPs) are a burgeoning area in the field of microbiome therapeutics, leveraging the benefits of probiotics and prebiotics. Probiotics are live microorganisms that confer health benefits when administered in adequate amounts, often by positively modulating the gut microbiota. They can aid in digestion, enhance immunity, and even contribute to mental well-being. Prebiotics, on the other hand, are compounds that selectively nourish beneficial gut bacteria, promoting their growth and activity. LBPs combine these elements, offering a targeted approach to microbiome modulation for various health conditions. By harnessing the symbiotic relationship between probiotics and prebiotics, LBPs hold promise in addressing gastrointestinal disorders, metabolic diseases, and even neurological conditions, paving the way for personalized and effective therapeutic interventions.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India